Short answer
Part D covers Wegovy for heart-risk reduction; the Bridge adds a weight-management path.
The Congressional Research Service says that after a 2024 FDA approval, Wegovy (semaglutide) can be covered under Medicare Part D to reduce the risk of heart attack and stroke in adults with cardiovascular disease. It says GLP-1 drugs used only for weight loss are excluded from Part D. CMS says the new GLP-1 Bridge, running July 1, 2026 through December 31, 2027, includes Wegovy among the weight-management drugs available to eligible beneficiaries.
Start here
What you actually came to find out
Plain answers first. Sources stay below for checking details.
For heart risk?
The CRS says Part D can cover Wegovy for cardiovascular risk reduction.
For weight loss alone?
The CRS says Part D excludes weight-loss-only use.
Is it in the Bridge?
CMS says yes, Wegovy is included in the GLP-1 Bridge.
Will the price change?
CMS says Wegovy was selected for negotiation, effective 2027.
Heart-risk use
Covered
The CRS says Part D can cover Wegovy for cardiovascular risk reduction after the 2024 approval.
Source trail: Congressional Research Service
Weight loss alone
Excluded
The CRS says Part D excludes GLP-1 drugs used only for weight loss.
Source trail: Congressional Research Service
The Bridge
Included
CMS says Wegovy is among the weight-management drugs in the GLP-1 Bridge.
Source trail: CMS
Price negotiation
Effective 2027
CMS says Wegovy was selected for Medicare drug price negotiation.
Source trail: CMS
The real distinction is the reason for the prescription: Wegovy for cardiovascular risk goes through Part D, while weight management has its own Bridge pathway.
Neutral landscape
The shape of the question
The Congressional Research Service is the main source because it explains the 2024 cardiovascular approval that opened Part D coverage for Wegovy.
Source trail: Congressional Research Service
The weight-loss boundary still applies, and the CRS says weight-loss-only use is excluded.
Source trail: Congressional Research Service
The Bridge adds a path, since CMS includes Wegovy among the Bridge weight-management drugs.
Source trail: CMS
Cost is changing, because CMS selected Wegovy for negotiation with prices effective in 2027.
Source trail: CMS
Curator core
What the authorities say
These sources are here for the reader who wants to check the work. The plain-English answer stays above them.
Source 01
Congressional Research Service
Medicare Coverage of GLP-1 Drugs
The Congressional Research Service summarizes Medicare coverage of GLP-1 drugs, including the statutory weight-loss exclusion and coverage for diabetes and cardiovascular indications.
Source framing
The Congressional Research Service says GLP-1 drugs are not covered under Part D when used for weight loss, but are covered for medically accepted indications such as type 2 diabetes and cardiovascular risk reduction.
Strongest for: the weight-loss exclusion and the covered medical indications
Read at Congressional Research ServiceSource 02
CMS
Medicare GLP-1 Bridge Prior Authorization Form
The CMS Bridge prior authorization form lists the Part D-eligible diagnoses that route to a Part D plan and the body-mass-index and lifestyle conditions for the Bridge.
Source framing
CMS says diagnoses like type 2 diabetes, cardiovascular risk reduction, obstructive sleep apnea, and MASH route to the Part D plan, while the Bridge covers weight management with body-mass-index and lifestyle conditions.
Strongest for: which diagnoses go to Part D versus the Bridge, and the Bridge conditions
Read at CMSSource 03
CMS
Medicare Drug Price Negotiation Selections
CMS announced the second cycle of Medicare drug price negotiations, which selected Ozempic, Rybelsus, and Wegovy, with negotiated prices effective in 2027.
Source framing
CMS says Ozempic, Rybelsus, and Wegovy were selected for Medicare drug price negotiation, with negotiated prices effective in 2027, and that Part D out-of-pocket spending is capped at $2,000 a year.
Strongest for: GLP-1 drug price negotiation and the Part D out-of-pocket cap
Read at CMSPlain-English forks
The forks people face
Most retirement questions hide a few smaller decisions. These are the practical pieces that change the plan.
Is it for heart-risk reduction or weight loss?
Why it matters: Cardiovascular risk goes through Part D; weight management has the Bridge.
In real life: This fork sets the pathway.
What to look at: What to look at: the CRS summary and the CMS Bridge form.
Do you meet the Bridge conditions?
Why it matters: The Bridge sets body-mass-index and health-condition criteria.
In real life: This fork decides Bridge eligibility.
What to look at: What to look at: the CMS Bridge prior authorization form.
Are you planning for 2027 prices?
Why it matters: CMS selected Wegovy for negotiation, effective 2027.
In real life: This fork affects future cost.
What to look at: What to look at: the CMS negotiation announcement.
Common questions
Quick answers
Short, plain answers for the questions people usually have next. The source trail stays available below.
Does Medicare cover Wegovy for heart health?+
The Congressional Research Service says that after a 2024 FDA approval, Part D can cover Wegovy to reduce the risk of heart attack and stroke in adults with cardiovascular disease.
Does Medicare cover Wegovy for weight loss?+
The CRS says GLP-1 drugs used only for weight loss are excluded from standard Part D, though the new Bridge adds a weight-management path.
Is Wegovy in the GLP-1 Bridge?+
CMS says Wegovy is among the weight-management drugs available through the GLP-1 Bridge from July 1, 2026 through December 31, 2027.
How is Wegovy different from Ozempic?+
Both are semaglutide, but Ozempic is approved for type 2 diabetes while Wegovy is approved for weight management and, since 2024, cardiovascular risk reduction.
Will Wegovy get cheaper under Medicare?+
CMS says Wegovy was selected for Medicare drug price negotiation, with negotiated prices effective in 2027.
How this page is curated
This page uses the Congressional Research Service summary, the CMS GLP-1 Bridge form and page, and the CMS drug-price-negotiation announcement. It separates the cardiovascular indication from weight management because Medicare covers them through different pathways.
Read the planner methodologyTrust anchor
Sources used on this page
Every source named above is listed here in one place.
CMS. Medicare GLP-1 Bridge Prior Authorization Form
https://www.cms.gov/glp-1-bridge.pdfCMS. Medicare Drug Price Negotiation Selections
https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lowerCongressional Research Service. Medicare Coverage of GLP-1 Drugs
https://www.congress.gov/crs-product/IF12758
Before you act on this
This plan is educational. It is not personalized financial, tax, or insurance advice. Projections illustrate the math, they do not predict the future. Talk to your own licensed financial professional before acting on any of it.